| Literature DB >> 28357072 |
Shinichi Utsugi1, Kazuo Azuma2, Tomohiro Osaki2, Yusuke Murahata2, Takeshi Tsuka2, Norihiko Ito2, Tomohiro Imagawa2, Yoshiharu Okamoto2.
Abstract
Canine brain tumors are best diagnosed using magnetic resonance imaging (MRI). However, opportunities of MRI examination are restricted due to its limited availability in veterinary facilities; thus, numerous canine brain tumors are diagnosed at an advanced stage. Therefore, development of a noninvasive diagnostic biomarker is required for the early detection of brain tumors. In the present study, plasma free amino acid (PFAA) profiles between dogs with and without brain tumors were compared. A total of 12 dogs with brain tumors, diagnosed based on clinical signs, and on the results of intracranial MRI and/or pathological examination were evaluated. In addition, eight dogs diagnosed with idiopathic epilepsy and 16 healthy dogs were also included. A liquid chromatography system with automated pre-column derivatization functionality was used to measure the levels of 20 amino acids. As a result, the levels of three amino acids (alanine, proline and isoleucine) were increased significantly (1.6-, 1.5- and 1.6-fold, respectively) in the plasma of dogs with brain tumors as compared with the levels in control dogs (all P<0.05). Thus, the PFAA levels of dogs with brain tumors differed from those of healthy dogs. The present study demonstrated that analysis of PFAA levels of dogs with brain tumors may serve as a useful biomarker for the early detection of canine brain tumors.Entities:
Keywords: brain tumor; dog; glioma; meningioma; plasma free amino acid
Year: 2016 PMID: 28357072 PMCID: PMC5351192 DOI: 10.3892/br.2016.825
Source DB: PubMed Journal: Biomed Rep ISSN: 2049-9434